Navigation Links
Lexicon Presents LX4211 Mechanism of Action Data at American Diabetes Association Meeting and Announces Commencement of Phase 2b Clinical Trial in Type 2 Diabetes
Date:6/27/2011

THE WOODLANDS, Texas, June 27, 2011 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, announced today that the company presented clinical data from a mechanistic study of LX4211, a dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and SGLT2), in patients with type 2 diabetes at the 71st Scientific Sessions of the American Diabetes Association (ADA) in San Diego, California.  In addition, the company announced that it has commenced enrollment of patients with type 2 diabetes in its Phase 2b clinical trial of LX4211.

Data from the mechanistic study demonstrated that a single dose of LX4211 significantly increased circulating levels of GLP-1 (active and total) and PYY, important regulators of glycemic and appetite control.  For more information on this program or to download a copy of the poster from the ADA meeting, please visit www.lexpharma.com.

The Phase 2b trial is a randomized, double-blind, placebo controlled study of LX4211 in approximately 285 adult patients (18-75 years) with type 2 diabetes who are not adequately controlled on metformin monotherapy.  Patients will be administered LX4211 in combination with standard metformin therapy over 12 weeks.  Doses will include 75 mg once daily, 200 mg once daily, 200 mg twice daily, 400 mg once daily or placebo.  The primary endpoint of the study is the change from baseline in HbA1c at Week 12.  Secondary endpoints will include percentage of patients achieving HbA1c < 7%, and changes in fasting plasma glucose, 3-hour glucose tolerance test, weight, blood pressure, and triglycerides.  The study will be conducted at ap
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
2. Lexicon Reports Initial Clinical Trial Results for LX1031, an Investigational New Drug for Irritable Bowel Syndrome
3. Lexicon Files Investigational New Drug Application for LX2931 as a Potential Treatment for Rheumatoid Arthritis
4. Lexicon Initiates Phase 2a Trial of LX6171 Drug Candidate for Cognitive Disorders
5. Lexicon Presents Clinical Data on LX1032 for Carcinoid Syndrome at European Neuroendocrine Tumor Society Meeting
6. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
7. Lexicons Drug Candidate LX1032 for Carcinoid Syndrome Receives Orphan Drug Designation From EMEA
8. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
9. Lexicon Announces Pricing of Common Stock in Public Offering
10. Lexicon Announces Completion of Public Offering of Common Stock
11. Lexicon Pharmaceuticals to Present at the 12th Annual BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 19, 2014 In today,s increasingly global ... presence to reflect the needs of a global ... meet the needs of key stakeholders while recognizing ... According to recent research by benchmarking firm, ... participating companies averaged more than $100,000 in annual ...
(Date:12/19/2014)... , December 18, 2014 ... application/module that is used to store, manipulate, and ... comprises a patient tracking and scheduling system, result ... of RIS with HIS and other databases improves ... registration and patient scheduling, patient list management, radiology ...
(Date:12/19/2014)... 2014  Decision Resources Group finds that the laparoscopic ... will increase to a value of over $4.3 ... expansion in the large direct energy device market. In ... adopted due to the advantages they offer and as ... from Decision Resources Group,s coverage of the U.S. laparoscopic ...
Breaking Medicine Technology:Building a Best-in-Class Pharma Global Brand Website 2The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 2The Global Radiology Information Systems Market is Expected to Grow at a CAGR of 7.5% from 2014 to 2019 3U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3
... October 21, 2011 At the ... (IDS)   in Barcelona, Spain (20-22 October 2011),   ... long-term, sustained efficacy and safety of   XEOMIN ... with dystonia. Dystonia is a particularly ...
... N.C., Oct. 21, 2011 SPX Corporation (NYSE: ... segment entered into a definitive agreement to acquire ... extraction, evaporation, vacuum and freeze drying technologies to the ... terms of the transaction were not disclosed.  The transaction ...
Cached Medicine Technology:Merz research Shows Long-term Benefits for Patients With Dystonia 2Merz research Shows Long-term Benefits for Patients With Dystonia 3Merz research Shows Long-term Benefits for Patients With Dystonia 4SPX to Acquire e&e, a Global Supplier of Extraction, Evaporation, Vacuum and Freeze Drying Technologies 2SPX to Acquire e&e, a Global Supplier of Extraction, Evaporation, Vacuum and Freeze Drying Technologies 3
(Date:12/21/2014)... AngelWeddingDress.com’s new collection of 2015 spring ... of 1,000 new designs in this collection, and all ... , AngelWeddingDress.com promises to provide the most ... essentials while many fashion trends come and go. If ... team at AngelWeddingDress.com is ready to assist. , ...
(Date:12/21/2014)... Dennis Thompson HealthDay Reporter ... tobacco smokers find e-cigarettes less addictive than traditional cigarettes, new ... often as they did regular cigarettes, thousands of ex-smokers said ... impulsive and irritable over their need to smoke, researchers reported. ... score was significantly less for e-cig use than for tobacco ...
(Date:12/21/2014)... 2014 The number of Mirena lawsuits ... litigation underway in New Jersey, Bernstein Liebhard LLP reports. ... claims involving the birth control IUD have now been ... filed by women who allege spontaneous migration of the ... perforations and other complications they were inadequately warned about ...
(Date:12/21/2014)... California (PRWEB) December 21, 2014 Serious ... search for Vintage 1967 Jm Morrison and the Doors International ... posters. This would also be the only time that ... concert was on Nov. 25, 1967. According to Hawley, ... D.C. They did play the Alexandria Roller Rink earlier ...
(Date:12/21/2014)... Over the past 39 years, NES ... of emergency departments across the nation, from quality of ... translated into an innovative suite of tools, systems, and ... enhance the patient experience. , NES Health, a ... management services for hospitals, announced the development and launch ...
Breaking Medicine News(10 mins):Health News:2015 Spring Wedding Dresses From AngelWeddingDress Just Released 2Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 2Health News:E-Cigarettes Less Addictive Than Regular Cigarettes, Study Finds 3Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuits Approach 1,400 in Bergen County Litigation, Bernstein Liebhard LLP Reports 3Health News:NES Health Launches Stipend Program for Emergency Physicians in Training to Financially Assist Emergency Department Doctors While They Learn 2
... new study shows that Multidetector CT (MDCT) without the use of ... This helps in avoiding the need for surgeons to do ... ,In the past, the best way to find ... contrast media then watch to see if and where the contrast ...
... Previous studies have suggested that drinking a lot of coffee ... result in miscarriage or premature delivery. ,A recent ... of a link between caffeine intake and pregnancy outcome. ... 1,000 women in the initial stages of pregnancy who drank ...
... licenses for inexpensive versions of heart disease and AIDS ... pharmaceutical bigwigs. Health Minister, Mongkol Songkhla, confirmed that the ... ,According to the Health Minister, the drugs are meant ... elaborate on whether the drugs would be generic substitutes ...
... have discovered that learning appears to slow the development of ... The finding suggests that the elderly, by keeping their minds ... The study appears in the Jan. 24 issue of the ... modified mice is the first to show that short but ...
... of the mineral selenium appear to reduce or slow ... selenium have been noted in HIV-positive patients, and evidence ... system function, the researchers report in the Jan. 22 ... ,"Those individuals who were treated with selenium displayed ...
... equally effective alternative therapy for controlling hot flushes and ... derived from progesterone may be as effective as estrogen ... synthetic version of the hormone progesterone, was first made ... available in an oral form – said Dr.Jerilynn Prior, ...
Cached Medicine News:Health News:Learning Slows Physical Progression of Alzheimer's Disease: Study 2Health News:Selenium Supplements May Slow Progression of HIV: Report 2Health News:Selenium Supplements May Slow Progression of HIV: Report 3
Light weight, clear imaging, attaches easily, perfect size, optional leg, table cart....
... powered torso and leg sections ... Table simultaneously lift body and ... mechanism raises and lowers legs ... positioning. A wide range of ...
... The RX600 is a versatile, fully ... range of built-in traction facilities, a powered ... make it extremely versatile too. ,<br.,In fact ... general surgery as it is for traction ...
When You Need Optimal Patient Comfort with Minimal Weight at a Nonunion Site...Demand The OrthoPak Noninvasive Bone Growth Stimulator. , ,Most Appropriate for the Proximal Femur, Metatarsal/Tar...
Medicine Products: